Comparison of HMG/HCG superovulation for AID with or without superactive GnRH agonist.
New methods of ovulation induction have been discovered and perfected in recent years. Among others, gonadotrophin-releasing hormone (GnRH) agonists are being used increasingly in the treatment of ovulatory infertility. In a prospective study, 24 women undergoing artificial insemination with donor sperm (AID) and facing failure of treatment because of ovulation disorders, were treated with human menopausal gonadotrophin/human chorionic gonadotrophin (HMG/HCG) superovulation with or without pituitary densensitization using a superactive luteinizing hormone-releasing hormone (LHRH) agonist, buserelin (BUS), Suprefact (Hoechst, Frankfurt a/Main, FRG). In 86 cycles stimulated with HMG/HCG no pregnancy occurred, whereas 12 pregnancies occurred in the same group of patients after a total of 43 BUS/HMG/HCG stimulation cycles. Superactive LHRH agonists have a definite place in the treatment of AID patients presenting with refractory ovulation disorders and/or luteal insufficiency.
Gerris
J
J
Department of Obstetrics and Gynaecology, University Hospital, Antwerp, Belgium.
Jacquemyn
Y
Y
Desmedt
E
E
Delbeke
L
L
Buytaert
P
P
D000281:Administration, Intranasal; D000328:Adult; D002064:Buserelin / Q000008:administration & dosage / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D005260:Female; D005498:Follicular Phase; D006801:Humans; D007315:Insemination, Artificial; D008596:Menotropins / Q000627:therapeutic use*; D008597:Menstrual Cycle / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects*; D010906:Pituitary Hormone-Releasing Hormones / Q000502:physiology*; D011247:Pregnancy; D013480:Superovulation / Q000187:drug effects*
D006063:Chorionic Gonadotropin; D010906:Pituitary Hormone-Releasing Hormones; D008596:Menotropins; D002064:Buserelin